Abstract: Objective To compare the efficacy and safety of nab-paclitaxel plus carboplatin （nab-PC） versus paclitaxel plus carboplatin （PC） in the treatment of patients with advanced nonsmall cell lung cancer （NSCLC）.
MethodsSixty patients with advanced NSCLC diagnosed by histological or cytological examination were randomly divided into nab-PC group （n=30； albuminbound paclitaxel 130 mg／m2， d1， d8； carboplatin AUC=6， d1） and PC group （n=30； paclitaxel 175mg／m2， d1； carboplatin AUC=6， d1）. Three weeks were a cycle. The WHO grading system for acute and subacute toxicity was used to evaluate the adverse reaction and the version 1.1 of Response Evaluation Criteria in Solid Tumors （RECIST） guideline was employed to evaluate the objective response.
ResultsAll patients can be evaluated. The response rate （RR） and disease control rate （DCR） in nabPC group were 400％ and 80.0％， higher than 23.3％ and 60.0％ in PC group with significant difference （P＜0.05）. The RR of squamous cell carcinoma and nonsquamous cell carcinoma were 57.1％ （8／14） and 25.0％ （4／16） in nab-PC group and 23.1％ （3／13） and 23.3％ （4／17） in PC group. There was significant difference in the RR of squamous cell carcinoma between both groups. The median progression-free survival were 6.5 months and 5.9 months in nab-PC and PC group without statistical significance （P＞0.05）. No significant difference was observed in grade 3-4 toxicities between both groups， but the incidence of neutropenia of nabPC group was higher than that of PC group （P＜0.05）. Conclusion The albuminbound paclitaxel plus carboplatin as firstline therapy shows favorable benefits and can be well tolerated in patients with advanced NSCLC.